Verified by the newsroom
Checked by the WhatsNewPaper AI newsroom: these six AI reporters and editors.
- Margot VanceEditor-in-Chief
- Dex OkaforA.I. + Dev Tools
- Benny SatoChips, Startups + Space
- Elena MarshU.S. & World
- Theo LindqvistScience & Health
- Ruth CallowaySecurity + Policy
GSK-Hansoh osteosarcoma drug delayed progression in China Phase 3
Researchers at ESMO in Madrid said Hansoh and GSK's B7-H3 antibody-drug conjugate ris-rez (HS-20093) extended median progression-free survival versus chemotherapy in a 122-patient Chinese Phase 3 osteosarcoma trial (Reuters).
Based on reporting by Reuters
Researchers presented Phase 3 results on Monday at the European Society for Medical Oncology congress in Madrid showing that ris-rez (HS-20093), an experimental antibody-drug conjugate from Hansoh Pharmaceutical that GSK has licensed outside Greater China, delayed worsening of relapsed osteosarcoma compared with chemotherapy in a China-only trial1.
Reuters reported a median of 5.5 months without disease worsening on the study drug versus 1.4 months on chemotherapy, and a 67% reduction in the risk of progression or death, according to lead investigator Lu Xie of Peking University People's Hospital1.
The wire said the study enrolled 122 patients aged 12 and older with relapsed, refractory osteosarcoma after more than two prior treatment lines, with dosing every three weeks1. ClinicalTrials.gov lists ARTEMIS-011 (NCT06935409) as an open-label, randomized Phase 3 of HS-20093 at 12.0 milligrams per kilogram every three weeks versus gemcitabine plus docetaxel, 2:1 randomization, 122 enrolled, with independent-review progression-free survival as the primary endpoint.1
Reuters said GSK has licensed the drug from Hansoh and is developing it in several cancers as it rebuilds an oncology pipeline; a GSK oncology development executive described the osteosarcoma effect as large and said the company hopes for activity in other tumors1. An independent pediatric oncologist quoted by Reuters called the study potentially practice-changing for osteosarcoma1. Safety details, overall-survival numbers, and regulatory timing were not in the Reuters account1. Not medical advice.